The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study
Bram Verstockt(KU Leuven), Silvio Danese(IRCCS Ospedale San Raffaele), Jean‐Frédéric Colombel(Mount Sinai Hospital), Séverine Vermeire(KU Leuven), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Simon Lichtiger(Mount Sinai Medical Center), Britta Siegmund(Humboldt-Universität zu Berlin), Andrés Yarur(Cedars-Sinai Medical Center), Fabio Cataldi(Pfizer (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Brian G. Feagan(Western University), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Remo Panaccione(University of Calgary), Rebecca Mosig, Florian Rieder(Cleveland Clinic)
Cited by 15
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k